NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with procarbazine, lomustine, and vincristine or temozolomide.

By Wolfgang Wick, C. Hartmann, C. Engel, M. Stoffels, J. Felsberg, F. Stockhammer, M. Sabel, S. Koeppen, R. Ketter, R. Meyermann and 10 more. Journal of Clinical Oncology, 2009

807 citations recorded by the source corpus.

Subfields: Epidemiology, Genetics, Pulmonary and Respiratory Medicine

View Paper: https://www.semanticscholar.org/paper/e33ba9c8300731c687f66be47dbd95f1b60afb6e

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Genetics

1. Michael Weller
2. Guido Reifenberger
3. Jill S. Barnholtz-Sloan
4. Q. Ostrom

Citations in the corpus

• Glioma Subclassifications and Their Clinical Significance (2017, background): “gliomas confer significantly better progression-free survival than in their IDH wild-type counterparts, irrespective of treatment received [19].”
• Patients with IDH1 wild type anaplastic astrocytomas exhibit worse prognosis than IDH1-mutated glioblastomas, and IDH1 mutation status accounts for the unfavorable prognostic effect of higher age: implications for classification of gliomas (2010, methodology): “Clinical and molecular data are derived from 94 patients with anaplastic astrocytoma treated in the NOA-04 trial [25] and from 51 patients with anaplastic astrocytoma and 237 patients with glioblastoma included in the prospective translational cohort study of the GGN [23].”
• The epidemiology of glioma in adults: a "state of the science" review. (2014, background): “outcomes.(30,41,42) Methylation of the O(6)-methylguanine-DNA methyltransferase (MGMT) gene promoter is a positive prognostic factor for glioblastomas, especially in the setting of chemotherapy with alkylating agents (eg, temozolomide).”
• High-grade glioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. (2014, background): “5 years, time to failure of both chemotherapy and radiation was similar whether patients were treated initially with chemotherapy (and received RT at first progression) or were treated with initial RT (and received chemotherapy at progression) [I, A] [42].”